23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human
genetics and biopharmaceutical company, reported its financial
results for the first quarter (Q1) of fiscal year 2024 (FY2024),
which ended June 30, 2023. 23andMe is the only company with
multiple U.S. Food and Drug Administration (FDA) authorizations for
over-the-counter genetic health reports. 23andMe also has the
largest crowdsourced platform for advanced genetic research, which
enables the Company to deliver ongoing genetic reports, new health
features and new risk predictions to customers annually. The
platform also accelerates the identification of novel drug
discovery programs rooted in human genetics across a spectrum of
disease areas. 23andMe’s platform was built to help people access,
understand, and benefit from the human genome.
“The Company made solid progress this past quarter across both
our Therapeutics and Consumer businesses,” said Anne Wojcicki,
Co-Founder and CEO of 23andMe. “We exited the exclusive drug
discovery phase of our GSK collaboration in a strong position to
capitalize on new partnerships and opportunities to work with a
number of biotech companies on genetics-based drug discovery. The
GSK collaboration proved the success of our approach to drug
discovery, producing more than 50 programs with targets discovered
or validated through the 23andMe database. We look forward to
leveraging our unique database, along with advancements in AI and
ML, to further advance Therapeutic programs at 23andMe, both
independently and with collaborators. In the Consumer business, we
saw strong reception to the new price point of our 23andMe+
subscription service, which we increased in recognition of the
substantial customer value we are delivering through additional
reports and features. The strategy is already showing favorable
results that will benefit the business in the long term.”
Recent Highlights
Consumer
- Continued to add to our member-exclusive content for 23andMe+
with the launch of new polygenic risk score (PRS) reports for
common conditions, including depression, lupus and panic attacks.
Member-exclusive content is a key element of our subscription
strategy that we continue to invest in.
- Added finer ancestry details for customers from
underrepresented groups (Indigenous American and Indigenous
Caribbean populations), increasing ancestry composition detail to
an industry-leading 2,500+ geographic regions.
Therapeutics
- 23ME-00610 Phase 1/2a clinical trial, an immuno-oncology
therapy targeting CD200R1 - currently enrolling patients in a
number of expansion cohorts to be evaluated for anti-tumor activity
in the Phase 2a portion of the study.
- Actively pursuing new collaborations with pharmaceutical
companies. Details on future collaborations will be shared when
available.
- Continuing to progress a number of programs with GSK developed
under the collaboration, with the exclusive target discovery
portion of the agreement now concluded.
Research
- Launched Sickle Cell Carrier Status Awareness Program with
Morehouse School of Medicine, Sickle Cell Foundation of Georgia;
aiming to increase access to information on sickle cell carrier
status, and offer resources to individuals with sickle cell trait
and sickle cell disease.
“Our first quarter of fiscal year 2024 was important for 23andMe
as we continued to optimize our Consumer business with increased
average selling prices (ASP’s) and margins,” said Joe Selsavage,
Interim Chief Financial and Accounting Officer of 23andMe. “We
continue to use a rigorous approach in the advancement of our
therapeutics portfolio and improve our cost structure to focus on
the most valuable opportunities. Our progress this quarter enables
us to raise our full year guidance for net loss and Adjusted EBITDA
deficit.”
FY2024 First Quarter Financial ResultsTotal
revenue for the three months ended June 30, 2023, was $61 million,
compared to $65 million for the same period in the prior year,
representing a decrease of 6%. The decrease was primarily driven by
lower Consumer Services revenue as we focused on driving improved
margins through higher average selling prices and marketing
efficiency, reducing advertising spend and discounting windows,
resulting in lower volumes of Personal Genome Service (PGS) kit
sales and Telehealth orders. This was partially offset by growth in
our subscription and Research Services revenue from the GSK
collaboration and other third parties.
Revenue from Consumer Services, which includes PGS, telehealth
and subscription services, represented approximately 79% of total
revenue for the three months ended June 30, 2023. Research Services
revenue accounted for approximately 21% of total revenue.
Operating expenses for the three months ended June 30, 2023,
were $140 million, compared to $115 million for the same period in
the prior year. The increase in operating expenses in the
three-month period was primarily due to a $22 million non-cash
stock based compensation expense associated with the acceleration
of an equity grant in connection with the termination of an
employee and continued investment in Therapeutics portfolio
advancement, partly offset by reductions in marketing advertising
spend aimed to improve advertising efficiency as noted
previously.
Net loss for the three months ended June 30, 2023, was $105
million, compared to a net loss of $90 million for the same period
in the prior year. The increase in the three-month period was
primarily attributable to higher operating expenses, including an
equity award acceleration as noted above, partially offset by
improvements in gross margins and an increase in interest income
from interest yields earned on cash held in money market funds.
Total Adjusted EBITDA (as defined below) for the three months
ended June 30, 2023, was a deficit of $50 million, compared to a
deficit of $50 million for the same period in the prior year. The
improvements in gross margins and marketing spend offset increases
in other operating expenses noted above, keeping Adjusted EBITDA
deficit flat between the comparative periods. Please refer to the
tables below for a reconciliation of U.S. GAAP to Non-U.S. GAAP
financial measures.
Balance Sheet 23andMe ended June 30, 2023 with
cash and cash equivalents of $314 million, compared to $387 million
as of March 31, 2023.
FY2024 Financial GuidanceThe Company’s full
year fiscal 2024 guidance is based on a conservative approach,
recognizing the current uncertainties in the general economy and
financial markets. Within the existing Consumer businesses of PGS
and telehealth, the Company is prioritizing the minimization of
cash burn over initiatives intended to create incremental top-line
growth. For those areas of the business expected to drive future
growth, and Therapeutics, the Company plans to focus on the most
strategically and financially valuable allocation of capital and
invest appropriately. Given the Company’s shift in focus to higher
margins rather than volume growth in PGS and telehealth, as well as
the end of the target discovery term of the GSK collaboration, the
Company does not foresee meaningful revenue contribution from these
areas of Consumer and Research Services in FY2024. The Company is
adjusting its full year guidance following Q1 FY2024 results.
Revenue guidance for FY2024, which will end on March 31, 2024, is
reaffirmed to be in the range of $255 million to $275 million, with
net loss now in the range of $345 million to $325 million. Full
year Adjusted EBITDA deficit is now projected to be in the range of
$180 to $160 million for fiscal year 2024.
The guidance assumes the following:
- we continue to advance our key therapeutic assets
- no additional revenue from new strategic collaborations
Conference Call Webcast Information 23andMe
will host a conference call at 4:30 p.m. Eastern Time today, August
8, 2023 to discuss the financial results for Q1 FY2024 and report
on business progress. The webcast can be accessed here
https://investors.23andme.com/news-events/events-presentations. A
webcast replay will be available at the same address for a limited
time within 24 hours after the event.
About 23andMe 23andMe is a genetics-led
consumer healthcare and therapeutics company empowering a healthier
future. For more information, please visit
investors.23andme.com.
Additional Information This press release shall
not constitute an offer to sell or a solicitation of an offer to
buy any of the securities, nor shall there be any sale of these
securities, in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding the future performance of
23andMe’s businesses in consumer genetics and therapeutics and the
growth and potential of its proprietary research platform. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding
23andMe’s strategy, financial position, funding for continued
operations, cash reserves, projected costs, plans, potential future
collaborations, and objectives of management, are forward-looking
statements. The words "believes," "anticipates," "estimates,"
"plans," "expects," "intends," "may," "could," "should,"
"potential," "likely," "projects," "predicts," "continue," "will,"
"schedule," and "would" or, in each case, their negative or other
variations or comparable terminology, are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking
statements are predictions based on 23andMe’s current expectations
and projections about future events and various assumptions.
23andMe cannot guarantee that it will actually achieve the plans,
intentions, or expectations disclosed in its forward-looking
statements and you should not place undue reliance on 23andMe’s
forward-looking statements. These forward-looking statements
involve a number of risks, uncertainties (many of which are beyond
the control of 23andMe), or other assumptions that may cause actual
results or performance to differ materially from those expressed or
implied by these forward-looking statements. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company’s filings with the Securities and Exchange Commission,
including under Item 1A, "Risk Factors" in the Company’s most
recent Annual Report on Form 10-K, as filed with the Securities and
Exchange Commission, and as revised and updated by our Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. The
statements made herein are made as of the date of this press
release and, except as may be required by law, 23andMe undertakes
no obligation to update them, whether as a result of new
information, developments, or otherwise.
Use of Non-GAAP Financial MeasuresTo supplement
the 23andMe’s unaudited condensed consolidated statements of
operations and unaudited condensed consolidated balance sheets,
which are prepared in conformity with generally accepted accounting
principles in the United States of America (GAAP), this press
release also includes references to Adjusted EBITDA, a non-GAAP
financial measure that is defined as net income (loss) before net
interest income (expense), net other income (expense), income tax
expenses (benefit), depreciation and amortization, impairment
charges, stock-based compensation expense, transaction-related
costs, and other items that are considered unusual or not
representative of underlying trends of our business, including but
not limited to: changes in fair value of warrant liabilities and
litigation settlements, if applicable for the periods presented.
23andMe has provided a reconciliation of net loss, the most
directly comparable GAAP financial measure, to Adjusted EBITDA at
the end of this press release.
Adjusted EBITDA is a key measure used by 23andMe’s management
and the board of directors to understand and evaluate operating
performance and trends, to prepare and approve 23andMe’s annual
budget and to develop short- and long-term operating plans. 23andMe
provides Adjusted EBITDA because 23andMe believes it is frequently
used by analysts, investors and other interested parties to
evaluate companies in its industry and it facilitates comparisons
on a consistent basis across reporting periods. Further, 23andMe
believes it is helpful in highlighting trends in its operating
results because it excludes items that are not indicative of
23andMe’s core operating performance. In particular, 23andMe
believes that the exclusion of the items eliminated in calculating
Adjusted EBITDA provides useful measures for period-to-period
comparisons of 23andMe’s business. Accordingly, 23andMe believes
that Adjusted EBITDA provides useful information in understanding
and evaluating operating results in the same manner as 23andMe’s
management and board of directors.
In evaluating Adjusted EBITDA, you should be aware that in the
future 23andMe will incur expenses similar to the adjustments in
this presentation. 23andMe’s presentation of Adjusted EBITDA should
not be construed as an inference that future results will be
unaffected by these expenses or any unusual or non-recurring items.
Adjusted EBITDA should not be considered in isolation of, or as an
alternative to, measures prepared in accordance with GAAP. Other
companies, including companies in the same industry, may calculate
similarly-titled non-GAAP financial measures differently or may use
other measures to evaluate their performance, all of which could
reduce the usefulness of Adjusted EBITDA as a tool for comparison.
There are a number of limitations related to the use of these
non-GAAP financial measures rather than net loss, which is the most
directly comparable financial measure calculated in accordance with
GAAP. Some of the limitations of Adjusted EBITDA include (i)
Adjusted EBITDA does not properly reflect capital commitments to be
paid in the future, and (ii) although depreciation and amortization
are non-cash charges, the underlying assets may need to be replaced
and Adjusted EBITDA does not reflect these capital expenditures.
When evaluating 23andMe’s performance, you should consider Adjusted
EBITDA alongside other financial performance measures, including
net loss and other GAAP results. Adjusted EBITDA is our best proxy
for cash burn. ContactsInvestor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
23andMe
Holding Co.Condensed Consolidated Statements of Operations
and Comprehensive Loss(In thousands, except share and per
share data)(Unaudited) |
|
|
Three Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
Revenue |
|
$ |
60,864 |
|
|
$ |
64,513 |
|
Cost of revenue |
|
|
30,184 |
|
|
|
39,023 |
|
Gross profit |
|
|
30,680 |
|
|
|
25,490 |
|
Operating expenses: |
|
|
|
|
|
|
Research and development |
|
|
62,329 |
|
|
|
52,009 |
|
Sales and marketing |
|
|
22,658 |
|
|
|
33,434 |
|
General and administrative |
|
|
50,740 |
|
|
|
29,643 |
|
Restructuring and other charges |
|
|
4,217 |
|
|
|
— |
|
Total operating expenses |
|
|
139,944 |
|
|
|
115,086 |
|
Loss from operations |
|
|
(109,264 |
) |
|
|
(89,596 |
) |
Other income (expense): |
|
|
|
|
|
|
Interest income, net |
|
|
4,307 |
|
|
|
245 |
|
Other income (expense), net |
|
|
333 |
|
|
|
(435 |
) |
Loss before income taxes |
|
|
(104,624 |
) |
|
|
(89,786 |
) |
Benefit from income taxes |
|
|
— |
|
|
|
254 |
|
Net loss |
|
|
(104,624 |
) |
|
|
(89,532 |
) |
Other comprehensive income
(loss), net of tax |
|
|
(334 |
) |
|
|
624 |
|
Total comprehensive loss |
|
$ |
(104,958 |
) |
|
$ |
(88,908 |
) |
Net loss per share of Class A
and Class B common stock attributable to common stockholders: |
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.23 |
) |
|
$ |
(0.20 |
) |
Weighted-average shares used
to compute net loss per share: |
|
|
|
|
|
|
Basic and diluted |
|
|
462,254,442 |
|
|
|
446,505,329 |
|
|
|
|
|
|
|
|
23andMe
Holding Co.Condensed Consolidated Balance
Sheets(In thousands, except share and per share
amounts) |
|
|
June 30, |
|
|
March 31, |
|
|
|
2023 |
|
|
2023 |
|
|
|
(Unaudited) |
|
|
|
|
ASSETS |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
314,351 |
|
|
$ |
386,849 |
|
Restricted cash |
|
|
1,399 |
|
|
|
1,399 |
|
Accounts receivable, net |
|
|
4,124 |
|
|
|
1,897 |
|
Inventories |
|
|
11,815 |
|
|
|
10,247 |
|
Deferred cost of revenue |
|
|
7,301 |
|
|
|
5,376 |
|
Prepaid expenses and other current assets |
|
|
21,286 |
|
|
|
19,224 |
|
Total current assets |
|
|
360,276 |
|
|
|
424,992 |
|
Property and equipment,
net |
|
|
35,704 |
|
|
|
38,608 |
|
Operating lease right-of-use
assets |
|
|
54,329 |
|
|
|
56,078 |
|
Restricted cash,
noncurrent |
|
|
6,974 |
|
|
|
6,974 |
|
Internal-use software,
net |
|
|
17,882 |
|
|
|
15,661 |
|
Intangible assets, net |
|
|
41,678 |
|
|
|
45,520 |
|
Goodwill |
|
|
351,744 |
|
|
|
351,744 |
|
Other assets |
|
|
2,612 |
|
|
|
3,021 |
|
Total assets |
|
$ |
871,199 |
|
|
$ |
942,598 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
12,748 |
|
|
$ |
12,924 |
|
Accrued expenses and other current liabilities |
|
|
50,215 |
|
|
|
66,430 |
|
Deferred revenue |
|
|
48,123 |
|
|
|
62,521 |
|
Operating lease liabilities |
|
|
7,823 |
|
|
|
7,541 |
|
Total current liabilities |
|
|
118,909 |
|
|
|
149,416 |
|
Operating lease liabilities,
noncurrent |
|
|
75,412 |
|
|
|
77,763 |
|
Other liabilities |
|
|
1,388 |
|
|
|
1,480 |
|
Total liabilities |
|
|
195,709 |
|
|
|
228,659 |
|
Stockholders'
equity |
|
|
|
|
|
|
Preferred stock - par value $0.0001, 10,000,000 shares authorized
as of June 30, 2023 and March 31, 2023; zero shares issued and
outstanding as of June 30, 2023 and March 31, 2023 |
|
|
— |
|
|
|
— |
|
Common stock, par value $0.0001 - Class A shares, 1,140,000,000
shares authorized, 304,011,272 and 293,020,474 shares issued and
outstanding as of June 30, 2023 and March 31, 2023,
respectively; Class B shares, 350,000,000 shares authorized,
168,084,278 and 168,179,488 shares issued and outstanding as of
June 30, 2023 and March 31, 2023, respectively |
|
|
47 |
|
|
|
46 |
|
Additional paid-in capital |
|
|
2,287,405 |
|
|
|
2,220,897 |
|
Accumulated other comprehensive income (loss) |
|
|
(954 |
) |
|
|
(620 |
) |
Accumulated deficit |
|
|
(1,611,008 |
) |
|
|
(1,506,384 |
) |
Total stockholders’ equity |
|
|
675,490 |
|
|
|
713,939 |
|
Total liabilities and stockholders’ equity |
|
$ |
871,199 |
|
|
$ |
942,598 |
|
23andMe Holding Co.Condensed Consolidated
Statements of Cash Flows(In
thousands)(Unaudited) |
|
|
Three Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
Cash flows from
operating activities: |
|
|
|
|
|
|
Net loss |
|
$ |
(104,624 |
) |
|
$ |
(89,532 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
|
Depreciation and amortization |
|
|
6,868 |
|
|
|
8,360 |
|
Amortization and impairment of internal-use software |
|
|
1,248 |
|
|
|
1,052 |
|
Stock-based compensation expense |
|
|
51,100 |
|
|
|
30,462 |
|
Loss (gain) on disposal of property and equipment |
|
|
(5 |
) |
|
|
9 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Accounts receivable, net |
|
|
(2,227 |
) |
|
|
460 |
|
Inventories |
|
|
(1,568 |
) |
|
|
(673 |
) |
Deferred cost of revenue |
|
|
(1,925 |
) |
|
|
1,154 |
|
Prepaid expenses and other current assets |
|
|
(1,928 |
) |
|
|
7,259 |
|
Operating right-of-use assets |
|
|
1,749 |
|
|
|
1,833 |
|
Other assets |
|
|
408 |
|
|
|
(765 |
) |
Accounts payable |
|
|
(2 |
) |
|
|
(19,154 |
) |
Accrued expenses and other current liabilities |
|
|
(1,889 |
) |
|
|
2,454 |
|
Deferred revenue |
|
|
(14,398 |
) |
|
|
(13,116 |
) |
Operating lease liabilities |
|
|
(2,070 |
) |
|
|
(2,179 |
) |
Other liabilities |
|
|
(92 |
) |
|
|
(664 |
) |
Net cash used in operating activities |
|
|
(69,355 |
) |
|
|
(73,040 |
) |
Cash flows from
investing activities: |
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(419 |
) |
|
|
(1,614 |
) |
Capitalized internal-use software costs |
|
|
(2,281 |
) |
|
|
(1,286 |
) |
Net cash used in investing activities |
|
|
(2,700 |
) |
|
|
(2,900 |
) |
Cash flows from
financing activities: |
|
|
|
|
|
|
Proceeds from exercise of stock options |
|
|
69 |
|
|
|
1,533 |
|
Payments for taxes related to net share settlement of equity
awards |
|
|
(121 |
) |
|
|
— |
|
Net cash provided by financing activities |
|
|
(52 |
) |
|
|
1,533 |
|
Effect of exchange rates on
cash and cash equivalents |
|
|
(334 |
) |
|
|
623 |
|
Net increase
(decrease) in cash, cash equivalents and restricted
cash |
|
|
(72,441 |
) |
|
|
(73,784 |
) |
Cash, cash equivalents and
restricted cash—beginning of period |
|
|
395,222 |
|
|
|
561,755 |
|
Cash, cash equivalents
and restricted cash—end of period |
|
$ |
322,781 |
|
|
$ |
487,971 |
|
Reconciliation of
cash, cash equivalents, and restricted cash within the condensed
consolidated balance sheets to the amounts shown in the condensed
consolidated statements of cash flows above: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
314,351 |
|
|
$ |
479,398 |
|
Restricted cash, current |
|
|
1,399 |
|
|
|
1,599 |
|
Restricted cash, noncurrent |
|
|
6,974 |
|
|
|
6,974 |
|
Total cash, cash equivalents
and restricted cash |
|
$ |
322,724 |
|
|
$ |
487,971 |
|
23andMe Holding Co.Total
Company and Segment Information and Reconciliation of Non-GAAP
Financial Measures(In
thousands)(Unaudited)
The Company’s revenue and Adjusted EBITDA by segment and for the
total Company is as follows:
|
|
Three Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
Segment Revenue:
(1) |
|
|
|
|
|
|
Consumer and Research Services |
|
$ |
60,864 |
|
|
$ |
64,513 |
|
Total revenue |
|
$ |
60,864 |
|
|
$ |
64,513 |
|
Segment Adjusted
EBITDA: |
|
|
|
|
|
|
Consumer and Research Services Adjusted EBITDA |
|
$ |
(5,602 |
) |
|
$ |
(16,997 |
) |
Therapeutics Adjusted EBITDA |
|
|
(31,138 |
) |
|
|
(18,465 |
) |
Unallocated Corporate (2) |
|
|
(13,060 |
) |
|
|
(14,253 |
) |
Total Adjusted EBITDA |
|
$ |
(49,800 |
) |
|
$ |
(49,715 |
) |
Reconciliation of net
loss to Adjusted EBITDA: |
|
|
|
|
|
|
Net loss |
|
$ |
(104,624 |
) |
|
$ |
(89,532 |
) |
Adjustments: |
|
|
|
|
|
|
Interest income, net |
|
|
(4,307 |
) |
|
|
(245 |
) |
Other (income) expense, net |
|
|
(333 |
) |
|
|
435 |
|
Income tax benefit |
|
|
— |
|
|
|
(254 |
) |
Depreciation and amortization |
|
|
4,478 |
|
|
|
5,104 |
|
Amortization of acquired intangible assets |
|
|
3,638 |
|
|
|
4,315 |
|
Stock-based compensation expense |
|
|
51,100 |
|
|
|
30,462 |
|
Transaction-related costs |
|
|
248 |
|
|
|
— |
|
Total Adjusted EBITDA |
|
$ |
(49,800 |
) |
|
$ |
(49,715 |
) |
(1) There was no Therapeutics revenue for the three months ended
June 30, 2023 and 2022.
(2) Certain department expenses such as Finance,
Legal, Regulatory and Supplier Quality, Corporate Communications,
Corporate Development, and CEO Office are not reported as part of
the reporting segments as reviewed by the CODM. These amounts are
included in Unallocated Corporate.
23andMe Holding Co.Reconciliation of GAAP Net Loss
Outlook to Non-GAAP Adjusted EBITDA Outlook(in
thousands)(Unaudited) |
|
|
Outlook for
the Year EndingMarch 31, 2024 |
|
|
|
as of August 8, 2023 |
|
|
|
Low |
|
|
High |
|
Reconciliation of
estimated net loss to adjusted EBITDA: |
|
|
|
|
|
|
GAAP Net Loss outlook |
|
$ |
(345,000 |
) |
|
$ |
(325,000 |
) |
Adjustments: |
|
|
|
|
|
|
Estimated interest (income) expense, net |
|
|
(11,423 |
) |
|
|
(11,423 |
) |
Estimated other (income) expenses, net |
|
|
(333 |
) |
|
|
(333 |
) |
Estimated depreciation and amortization |
|
|
19,681 |
|
|
|
19,681 |
|
Estimated amortization of acquired intangible assets |
|
|
11,449 |
|
|
|
11,449 |
|
Estimated stock-based compensation expense |
|
|
145,378 |
|
|
|
145,378 |
|
Estimated transaction-related costs |
|
|
248 |
|
|
|
248 |
|
Non-GAAP adjusted EBITDA outlook |
|
$ |
(180,000 |
) |
|
$ |
(160,000 |
) |
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024